Human monoclonal antibody having fat-reducing effect
US8124080B2 · kind B2 · utility
1Cited by
10References
27Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 12, 2004 |
| Grant date | Feb 28, 2012 |
| Priority date | — |
| Expiry date | Apr 14, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A purified polypeptide having an amino acid sequence that is substantial identical with the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, or both, in which the polypeptide binds low density lipoproteins (LDL) or oxidized LDL (oxLDL), or both, and particularly binds well to LDL cholesterol and oxidized LDL cholesterol. The polypeptide may be used in combination with conventional adjuvants or carrier substances for producing a drug having a fat-reducing effect and for producing drugs for aiding in the treatment of renal diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.